Lilly’s Next-Generation Obesity Shot Clears Another Hurdle
Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company
Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and Drug Administration approval early next year, later than investors hoped, due to the complexity of the approval pathway. Bloomberg's Madison Muller joins to discuss. Weekdays 7am-6pm ET Saturday & Sunday 7am-10am ET WATCH HERE Subscribe to our Podcasts Bloomberg Daybreak Bloomberg Surveillance Bloomberg Intelligence Balance of Power Bloomberg Businessweek Listen on Apple CarPlay and Android Auto with the Bloomberg Business app Apple CarPlay Android Auto Visit our YouTube channels Bloomberg Podcasts Bloomberg Television Bloomberg Originals Quicktake
The BriefWire